PuraPharm (HKG:1498) agreed to issue HK$20 million of 6% convertible bonds maturing in two years to Protoss Global Opportunities Fund, according to a Thursday Hong Kong bourse filing.
The bonds are convertible into a maximum of a little over 40.8 million conversion shares at HK$0.49 apiece.
The shares represent around 7.08% of the traditional Chinese medicine company's enlarged issued share capital.